Magnesium Salts Composition for Topical Skin Inflammation
Summary
The USPTO published patent application US20260108553A1 on April 23, 2026, filed by Instituto de Dermatología Ignacio Umbert, S.L. The application covers a composition comprising at least one magnesium salt, at least one non-magnesium salt, at least one antioxidant, and at least one plant extract, intended for treating skin inflammation pathologies. CPC classifications span A61K categories including magnesium compounds, antioxidants, and botanical extracts.
“The composition of the invention is intended for the treatment of pathologies of inflammation of the skin.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published application US20260108553A1 covers a dermatological composition combining magnesium salts with non-magnesium salts, antioxidants, and plant extracts for treating inflammatory skin conditions. Filing date was July 17, 2024, with application number 18997843. The published application does not grant enforceable patent rights — it makes the claims publicly available during examination.
Manufacturers and pharmaceutical companies developing topical anti-inflammatory formulations should note the specific combination of magnesium salts with botanical extracts and antioxidants as a claimed approach. Legal teams advising on formulation freedom should review the CPC classifications (A61K 33/06, A61K 36 series) to assess potential overlap with existing patents or ongoing development programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MAGNESIUM SALTS COMPOSITION
Application US20260108553A1 Kind: A1 Apr 23, 2026
Assignee
Instituto de Dermatología Ignacio Umbert, S.L.
Inventors
Ignacio UMBERT MILLET
Abstract
The present invention relates to a composition, characterised in that it comprises at least one magnesium salt, at least one salt not comprising magnesium, at least one antioxidant, and at least one plant extract. The composition of the invention is intended for the treatment of pathologies of inflammation of the skin.
CPC Classifications
A61K 33/06 A61K 33/14 A61K 33/16 A61K 36/16 A61K 36/23 A61K 36/258 A61K 36/28 A61K 36/38 A61K 36/48 A61K 36/537 A61K 36/77 A61K 36/82 A61K 36/899 A61K 45/06 A61P 17/00
Filing Date
2024-07-17
Application No.
18997843
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.